Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/116161
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCook, J.en
dc.contributor.authorHudson, I.en
dc.contributor.authorHarrison, L.en
dc.contributor.authorDean, B.en
dc.contributor.authorColman, P.en
dc.contributor.authorWerther, G.en
dc.contributor.authorWarne, G.en
dc.contributor.authorCourt, J.en
dc.date.issued1989en
dc.identifier.citationDiabetes, 1989; 38(6):779-783en
dc.identifier.issn0012-1797en
dc.identifier.issn1939-327Xen
dc.identifier.urihttp://hdl.handle.net/2440/116161-
dc.description.abstractA double-blind controlled trial of azathioprine (2 mg.kg-1.day-1) was conducted with 49 patients aged 2-20 yr (mean 10.8 yr) who had newly diagnosed type I (insulin-dependent) diabetes. Patients were randomly assigned to receive either azathioprine (n = 24) or placebo (n = 25) for 12 mo, beginning within the 20-day period after diagnosis. Baseline clinical and metabolic characteristics did not differ between the two groups. No patient experienced complete remission, defined as restoration of normal carbohydrate tolerance without other treatment. Partial remission, defined as good metabolic control (hemoglobin A1c less than or equal to 7.9%, preprandial blood glucose less than or equal to 8 mM with an insulin dose of less than 0.5 U.kg-1.day-1), occurred in 10 placebo (40%) and 7 azathioprine (29%) patients at 6 mo and in 4 placebo (16%) and 4 azathioprine (17%) patients at 12 mo (differences not significant). Fasting plasma C-peptide was significantly greater in the azathioprine-treated group at 3 and 6 mo, but this difference was not sustained. C-peptide responses to a standard meal and the frequency of islet cell and insulin antibodies did not differ between the two groups over the 12-mo period. Azathioprine caused no significant side effects. We conclude that in the dosage used, and despite early effects on endogenous insulin secretion, azathioprine alone does not influence the remission phase in children with newly diagnosed type I diabetes.en
dc.description.statementofresponsibilityJennifer J Cook, Irene Hudson, Leonard C Harrison, Brian Dean, Peter G Colman, Georgea Werther, Garry L Warne and John M Courten
dc.language.isoenen
dc.publisherAmerican Diabetes Associationen
dc.rightsCopyright © 1989 by the American Diabetes Associationen
dc.subjectDiabetes Mellitus, Type 1; Azathioprine; Insulin; C-Peptide; Hemoglobin A, Glycosylated; Blood Glucose; Double-Blind Method; Clinical Trials as Topicen
dc.titleDouble-blind controlled trial of azathioprine in children with newly diagnosed type I diabetesen
dc.typeJournal articleen
dc.identifier.rmid0030076130en
dc.identifier.doi10.2337/diab.38.6.779en
dc.identifier.pubid173807-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS06en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidCook, J. [0000-0003-4448-8629]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.